Topical heparin as an effective and safe treatment for patients with capecitabine-induced hand-foot syndrome: results of a phase IIA trial supported by proteomic profiling of skin biopsies.
capecitabine
hand-foot syndrome
heparin
palmar-plantar erythrodysesthesia
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
09
2021
accepted:
23
02
2022
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
1
4
2022
Statut:
epublish
Résumé
Hand-foot syndrome (HFS) is a common adverse reaction associated with capecitabine chemotherapy that significantly affects the quality of life of patients. This study evaluates the safety and effectiveness of a topical heparin (TH) treatment on the clinical manifestations and anatomopathological alterations of capecitabine-induced HFS. In addition, we performed proteome profiling of skin biopsies obtained from patients with HFS at baseline and after heparin treatment. Patients with grade ⩽ 2 HFS associated with capecitabine were included in this study. The primary end point was the effectiveness of TH in reducing HFS of any grade. Clinical improvement was evaluated by clinicians, and an improvement was perceived by patients who performed a weekly visual analog scale questionnaire. Secondary end points included a comparative histological analysis and protein expression in skin biopsies at baseline and after 3 weeks of HT treatment. Proteomic profiling was carried out using quantitative isobaric labelling and subsequently validated by a T-array. Twenty-one patients were included in the study. The median TH treatment time was 7.6 weeks (range = 3.6-41.6 weeks), and the median response time was 3.01 weeks (95% CI = 2.15-3.97). At the end of treatment, 19 of 21 patients (90.48%) responded to treatment with a decrease in one or more grades of HFS. None of the patients experienced adverse effects related to TH usage, nor did they suspend chemotherapy treatment. The main findings observed in skin biopsies after treatment were a decrease in hyperkeratosis and lymphocytic infiltrates. The proteomic analysis showed altered expression of 34 proteins that were mainly related to wound healing, cell growth, and the immune response. Based on our results, topical heparin is an effective and safe treatment for clinical manifestations of HFS, probably due to the restauration of skin homeostasis after heparin treatment, as supported by our proteomics-derived data. EudraCT 2009-018171-13.
Sections du résumé
Background
UNASSIGNED
Hand-foot syndrome (HFS) is a common adverse reaction associated with capecitabine chemotherapy that significantly affects the quality of life of patients. This study evaluates the safety and effectiveness of a topical heparin (TH) treatment on the clinical manifestations and anatomopathological alterations of capecitabine-induced HFS. In addition, we performed proteome profiling of skin biopsies obtained from patients with HFS at baseline and after heparin treatment.
Methods
UNASSIGNED
Patients with grade ⩽ 2 HFS associated with capecitabine were included in this study. The primary end point was the effectiveness of TH in reducing HFS of any grade. Clinical improvement was evaluated by clinicians, and an improvement was perceived by patients who performed a weekly visual analog scale questionnaire. Secondary end points included a comparative histological analysis and protein expression in skin biopsies at baseline and after 3 weeks of HT treatment. Proteomic profiling was carried out using quantitative isobaric labelling and subsequently validated by a T-array.
Results
UNASSIGNED
Twenty-one patients were included in the study. The median TH treatment time was 7.6 weeks (range = 3.6-41.6 weeks), and the median response time was 3.01 weeks (95% CI = 2.15-3.97). At the end of treatment, 19 of 21 patients (90.48%) responded to treatment with a decrease in one or more grades of HFS. None of the patients experienced adverse effects related to TH usage, nor did they suspend chemotherapy treatment. The main findings observed in skin biopsies after treatment were a decrease in hyperkeratosis and lymphocytic infiltrates. The proteomic analysis showed altered expression of 34 proteins that were mainly related to wound healing, cell growth, and the immune response.
Conclusion
UNASSIGNED
Based on our results, topical heparin is an effective and safe treatment for clinical manifestations of HFS, probably due to the restauration of skin homeostasis after heparin treatment, as supported by our proteomics-derived data.
Trial registration
UNASSIGNED
EudraCT 2009-018171-13.
Identifiants
pubmed: 35356259
doi: 10.1177/17588359221086911
pii: 10.1177_17588359221086911
pmc: PMC8958526
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17588359221086911Informations de copyright
© The Author(s), 2022.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
FASEB J. 2003 Apr;17(6):575-91
pubmed: 12665470
J Clin Oncol. 2015 Aug 1;33(22):2444-9
pubmed: 26124485
J Histochem Cytochem. 2002 Jan;50(1):1-10
pubmed: 11748289
Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18513-8
pubmed: 24167246
Biochemistry. 1999 Feb 23;38(8):2523-34
pubmed: 10029547
Cancer Res. 2014 Nov 1;74(21):6318-29
pubmed: 25213322
J Clin Aesthet Dermatol. 2016 Apr;9(4 Suppl 1):S2-S8
pubmed: 28936279
Toxicol Pathol. 2016 Jun;44(4):555-63
pubmed: 26940714
Biol Cell. 2014 Jul;106(7):203-18
pubmed: 24698078
J Biomed Mater Res A. 2003 Nov 1;67(2):517-23
pubmed: 14566793
BMJ Open. 2020 Oct 6;10(10):e038276
pubmed: 33028559
Nat Rev Cancer. 2008 Dec;8(12):976-90
pubmed: 19029958
Am J Clin Dermatol. 2000 Jul-Aug;1(4):225-34
pubmed: 11702367
Annu Rev Biochem. 1999;68:729-77
pubmed: 10872465
Ann Oncol. 2012 May;23(5):1348-1353
pubmed: 21940785
JAMA Oncol. 2017 Nov 01;3(11):1538-1545
pubmed: 28715540
Oncology (Williston Park). 2004 Aug;18(9):1161-8, 1173; discussion 1173-6, 1181-4
pubmed: 15471200
Biochem Biophys Res Commun. 2012 Jul 13;423(4):647-53
pubmed: 22683330
Matrix Biol. 2015 Apr;43:71-84
pubmed: 25779637
Biochim Biophys Acta. 2015 Dec;1850(12):2563-72
pubmed: 26409143
Arch Dermatol. 2011 Dec;147(12):1418-23
pubmed: 22184763
Ann Oncol. 2015 Oct;26(10):2017-26
pubmed: 26034039
J Biol Chem. 2010 Oct 29;285(44):33867-74
pubmed: 20729553
J Biol Chem. 2010 Feb 5;285(6):3722-3729
pubmed: 19959474
Eur J Immunol. 2011 Mar;41(3):645-56
pubmed: 21264853
Chem Res Toxicol. 2016 Oct 17;29(10):1591-1601
pubmed: 27631426
J Biol Chem. 2002 Oct 11;277(41):38571-8
pubmed: 12163502
J Invest Dermatol. 2015 Jul;135(7):1893-1902
pubmed: 25739049
Expert Opin Drug Saf. 2016 Dec;15(12):1625-1633
pubmed: 27718746
Int J Mol Sci. 2020 Sep 16;21(18):
pubmed: 32947991
Am J Clin Oncol. 2003 Oct;26(5):435-6
pubmed: 14528066
Oncol Rev. 2020 May 13;14(1):442
pubmed: 32431787
J Thromb Haemost. 2003 Dec;1(12):2554-60
pubmed: 14675092
Clin Exp Dermatol. 2021 Jun;46(4):629-635
pubmed: 33190278
Breast. 2006 Jun;15(3):414-24
pubmed: 16188440
J Clin Pharmacol. 2015 Oct;55(10):1109-18
pubmed: 25880826
J Clin Invest. 2003 Feb;111(4):487-95
pubmed: 12588887
Biochim Biophys Acta Mol Cell Res. 2020 Jun;1867(6):118677
pubmed: 32057918
PLoS One. 2013 Oct 16;8(10):e77806
pubmed: 24147081
Ther Adv Med Oncol. 2019 Apr 15;11:1758835919838964
pubmed: 31019570
J Dtsch Dermatol Ges. 2010 Sep;8(9):652-61
pubmed: 20482685
J Oncol Pharm Pract. 2006 Sep;12(3):131-41
pubmed: 17022868
Clin Colorectal Cancer. 2006 Nov;6(4):278-87
pubmed: 17241512
Nat Methods. 2009 May;6(5):359-62
pubmed: 19377485
Pathol Res Pract. 2015 Nov;211(11):816-23
pubmed: 26235036
Br J Pharmacol. 2007 Sep;152(2):230-9
pubmed: 17641676
Cancers (Basel). 2020 Jul 24;12(8):
pubmed: 32722137
J Invest Dermatol. 2004 May;122(5):1225-34
pubmed: 15140226
J Eur Acad Dermatol Venereol. 2014 Apr;28(4):405-14
pubmed: 23924267
AAPS PharmSciTech. 2020 Nov 8;21(8):310
pubmed: 33164131
N Engl J Med. 2017 Jun 1;376(22):2147-2159
pubmed: 28564564
Biochim Biophys Acta. 1993 Jan 22;1180(3):225-30
pubmed: 8422426
J Clin Oncol. 2005 Jul 1;23(19):4424-9
pubmed: 15994152
Br J Clin Pharmacol. 2008 Jul;66(1):88-95
pubmed: 18341672
Asia Pac J Clin Oncol. 2010 Sep;6(3):155-60
pubmed: 20887495